CSRxP Statement On The Introduction Of The Hatch-Waxman Integrity Act

Dec 12, 2018

For Immediate Release:
Contact: Lauren Blair
(201) 213-5004
[email protected]

Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) today issued the following statement in response to the introduction of the Hatch-Waxman Integrity Act:

“Big Pharma has been gaming the U.S. patent system for decades, fortifying their monopolies with frivolous patents that block out more affordable drugs.  The bill introduced today reinforces that status-quo, protecting the price-gouging pharmaceutical industry at the expense of hardworking families.

“By taking away the ability of generic and biosimilar drug manufacturers to call trivial, unnecessary patents into question, this bill is a major step backward in lowering drug prices.

“At a time when one in four patients cannot afford to take their medications as prescribed, lawmakers should be looking at ways to increase competition, not discourage it.  Part of that process means breaking down the patent fortresses behind which Big Pharma has been hiding.” 


About the Campaign for Sustainable Rx Pricing

The Campaign for Sustainable Rx Pricing (CSRxP) is a broad-based coalition of leaders – physicians, nurses, hospitals, consumers, health plans, PBMs, pharmacists, and businesses – promoting bipartisan, market-based solutions to lower drug prices in America.